Date of Award

12-2024

Document Type

Dissertation

Degree Name

Doctor of Medical Science (DMSc)

First Advisor

Jason Brumitt

Abstract

Severe atopic dermatitis significantly impairs the quality of life for infants and young children, along with their family members and caregivers. Atopic dermatitis is a chronic inflammatory disease of the skin. It is characterized by pruritic, erythematous, and xerotic skin. The prevalence of atopic dermatitis in the pediatric population is much greater than in adults; it is estimated that approximately 15-20% of children worldwide are affected by this condition. Although the majority of these children achieve spontaneous remission in adulthood, mild to moderate disease may often be debilitating and lead to a lower quality of life.

Previously, the only approved systemic treatment for atopic dermatitis in children younger than six years were glucocorticoids. However, there are substantial safety concerns associated with the use of glucocorticoids in young children. Glucocorticoids range in potency and aid in reducing the production of cytokines and lowering skin inflammation.While these medications are highly effective, they pose the risk of dependence, reaction to withdrawal, and skin atrophy.

Share

COinS